GILD - Company ID 0000882095
The table below shows GILEAD SCIENCES, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.30B | $7.80B | $6.96B | $7.77B | $7.08B | $6.67B |
| Cost of revenue | $1.57B | $1.58B | $1.45B | $1.57B | $1.50B | $1.54B |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
GILEAD SCIENCES, INC. reported annual revenue of $29.44B for fiscal year 2025. That is up 2.4% from $28.75B in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $30.39B (FY 2016) to $29.44B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.64B |
| $1.92B |
| $1.45B |
| $1.36B |
| $1.36B |
| $1.26B |
| Operating income | $3.46B | -$10.39B | $2.59B | $3.33B | $2.47B | $2.24B |
| Income tax | $634.00M | $242.00M | $559.00M | $589.00M | $468.00M | $334.00M |
| Net income | $2.43B | -$10.50B | $2.02B | $3.05B | $1.96B | $1.31B |
| EPS (diluted) | $1.94 | -$8.45 | $1.61 | $2.43 | $1.56 | $1.04 |